ARCHIVES

New Drug for Lymphoma Enters Phase II Trial

This article is from The Cancer Letter archive.

Vol. 27 No. 5 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

ODAC Meets at ASCO, Recommends Approval Of Dasatinib For CML.

June 9, 2006

“Forward Funding” Will Cost NCI $38 Million, 270 Grants, As OMB Legally Impounds FY 1985 Money

February 1, 1985

NTP Board Approves Four New Concepts

October 8, 1982

Barret’s Less of a Risk Factor For Cancer of the Esophagus

June 24, 2011

Funding Opportunity: PanCAN Offering $4.1 Million in Research Grants

September 12, 2014

Also New AACR President Lynn Matrisian plans emphasis on enhancing communication.

April 2, 2004